

10 November 2016

ASX Code: MXC

Cleansing Prospectus Closed

MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) confirms the offer under the Cleansing Prospectus dated 9 November 2016 has now closed and no new options were issued under the Cleansing Prospectus.

The Cleansing Prospectus was prepared for the purpose of section 708A(11) of the Corporations Act to remove any trading restrictions on the sale of the 35,000,000 Listed Options issued by the Company today.

-Ends-

For further information, please contact:

Media Enquiries

Andrew Ramadge
Account Director
Media and Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma CBD cosmetics.